Korro Bio's OPERA platform offers precise RNA editing for genetic diseases like Alpha-1 antitrypsin deficiency. Learn more on ...

The US Food and Drug Administration has approved fitusiran for bleeding prophylaxis in hemophilia A and B with or without ...

The decision to expand the development plan follows recently reported promising preclinical findings demonstrating that ...

Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, today highlighted the significance of the U.S. Food and Drug Administration's (FDA) approval of Qfitliatm (fitusiran), the sixth ...

New research led by the University of Portsmouth has revealed how Duchenne muscular dystrophy (DMD), best known for causing ...

The last week’s events in Queensland won’t have assuaged any fears over planning for the biggest show on earth.

Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitors Qfitlia (fitusiran), the first ...

First patient in Cohort four has been treated with TTX-MC138 Ten patients have been treated with TTX-MC138 at escalating dose levels Additional patients being evaluated ...

New research led by the University of Portsmouth has revealed how Duchenne muscular dystrophy (DMD), best known for causing ...

Learn more about whether Alvotech or Twist Bioscience Corporation is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

In a laboratory in Ulsan, South Korea, scientists have quietly pulled off what might become one of the most important ...